Lakewood-Amedex Biotherapeutics Inc, a clinical-stage biotech firm focused on developing a new category of powerful, rapid-acting, broad-spectrum antimicrobials known as the Bisphosphocin® class, has announced the addition of Joseph Tucker, Ph.D., to its Board of Directors. Dr. Tucker, who currently serves as Chief Executive Officer of Enveric Biosciences (Nasdaq: ENVB), joins the board following the company’s recent direct listing on Nasdaq. His appointment marks an important move to enhance governance and strategic direction as the company pursues its expansion plans.

With over 20 years of experience in the biotechnology sector, Dr. Tucker brings extensive leadership expertise across both public and private organizations, covering the full spectrum from early discovery to advanced-stage drug development. He leads Enveric Biosciences, a company dedicated to developing innovative neuroplastogenic small-molecule therapies aimed at treating neuropsychiatric and neurological conditions.

Kelvin Cooper, Ph.D., CEO of Lakewood-Amedex Biotherapeutics, noted that Dr. Tucker offers a strong blend of public company leadership, capital markets knowledge, and drug development expertise. He emphasized that Dr. Tucker’s experience in building and scaling biotech companies, along with his familiarity with public market dynamics, makes him a valuable addition to the board at a crucial stage. Following the Nasdaq listing, the company is prioritizing accelerated growth, and Dr. Tucker’s perspective is expected to support the advancement of its lead candidate, Nu-3, and broader pipeline development.

At Enveric, Dr. Tucker has overseen several strategic financing efforts and pipeline expansion initiatives, including progress toward a first-in-human clinical trial for its lead program, EB-003. Before joining Enveric, he held senior leadership roles—including CEO, Executive Chairman, and Director—at multiple biotechnology firms such as Willow Biosciences and Stem Cell Therapeutics. In these roles, he guided organizations through public offerings, mergers and acquisitions, and the development of clinical programs across diverse therapeutic areas. Throughout his career, he has raised over $100 million in funding, secured substantial non-dilutive capital, and completed numerous partnerships and licensing agreements.

Commenting on his new role, Dr. Tucker expressed enthusiasm about joining Lakewood-Amedex Biotherapeutics during a transformative period. He highlighted that the company’s Nasdaq listing creates a strong foundation for future growth and noted the promising potential of Nu-3 in tackling the global issue of antibiotic resistance. He also underscored the importance of developing new treatments for infected diabetic foot ulcers, an area with significant unmet medical need, and stated his eagerness to collaborate with the team to unlock the platform’s full potential.

Jazz Pharmaceuticals plc announced that it will share six research abstracts—including one oral presentation—at the 2026 American Academy of Neurology (AAN) Annual Meeting, scheduled for April 18–22, 2026, in Chicago.

These presentations highlight the scope of Jazz’s neuroscience work across epilepsy and sleep disorders. The data include new clinical findings on Epidiolex® (cannabidiol) in patients with conditions such as Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), tuberous sclerosis complex (TSC), and other difficult-to-treat epilepsies, as well as research on Xywav® (a mixed oxybate oral solution) in individuals with narcolepsy.

Jessa Alexander, Ph.D., who leads the neuroscience therapeutic area in global medical and scientific affairs at Jazz Pharmaceuticals, noted that the company remains committed to addressing unmet needs in rare neurological conditions. She emphasized that ongoing studies of Epidiolex and Xywav are helping deepen insights into these complex disorders, better reflect patient experiences, and guide research efforts toward improving care where gaps still exist.

Key highlights from the meeting include:

All abstracts from the 2026 AAN Annual Meeting are available online.

At Lenovo Tech World ’24, Lenovo, a global technology leader, partnered with the Scott-Morgan Foundation (SMF) to introduce an AI-powered solution aimed at enhancing communication for individuals with amyotrophic lateral sclerosis (ALS) and other severe disabilities. This innovative technology leverages generative AI to address accessibility challenges, underscoring a shared commitment to making AI more inclusive and impactful.

The solution integrates a circular keyboard interface designed by SMF and Lenovo, predictive AI developed by Lenovo, personalized voice replication from ElevenLabs, hyper-realistic avatars by D-ID, and eye-tracking technology from IrisBond. Together, these components enable precise, fast, and deeply personalized communication.

Currently undergoing testing with SMF’s ALS community and leading clinicians, this initiative builds on years of collaboration between SMF and Lenovo, aiming to scale assistive technology for those with ALS—a progressive neurodegenerative disease that often leads to total paralysis—and other conditions. The project opens new possibilities for transforming the lives of people with disabilities.

The event highlighted a touching story of a father diagnosed with ALS using the technology to narrate stories and sing to his children in his own voice. Linda Yao, Lenovo's Vice President of AI Solutions and Services, described the initiative as a testament to the transformative potential of AI, calling it "Smarter AI for All." She emphasized Lenovo’s commitment to working with compassionate partners like SMF to leverage AI for meaningful impact.

LaVonne Roberts, SMF’s Executive Director, highlighted the mission of breaking down barriers and democratizing life-changing technologies, envisioning a world where even those with severe disabilities can fully express themselves through advanced technology. She noted that over 500 million people globally face communication challenges due to neurological or muscular conditions, and this work has the potential for widespread impact.

Erin Taylor, a disability advocate living with ALS, demonstrated the technology at the event. She expressed excitement about speaking with a pre-diagnosis voice and contributing to the development of smarter, more inclusive technologies. Lenovo also showcased an integrated prototype designed with human-centric principles and cutting-edge AI.

Traditional voice banking has often been labor-intensive and emotionally limited, but advancements in AI have transformed this field. ElevenLabs CEO Mati Staniszewski described the breakthrough in creating expressive, on-demand voices even from limited or degraded samples. Similarly, D-ID’s lifelike avatar technology, based on minimal inputs like still images, enhances the solution’s scalability and realism.

The technology currently operates on Lenovo’s ThinkPad x12 detachable PC, which offers both portability and compatibility with IrisBond’s precise eye-tracking system. Eduardo Jauregui Torrecilla, CEO of IrisBond, highlighted the transformative potential of AI in empowering people with conditions like ALS or cerebral palsy to communicate effectively.

The initiative honors the vision of Dr. Peter Scott-Morgan, a pioneering roboticist who dreamed of revolutionizing assistive technology before his passing in 2022. Andrew Morgan, CEO of SMF, emphasized the critical role of AI in driving this progress and the ongoing need to advocate for these solutions to ensure accessibility for all.